Skip to content

Dysmyelination With Jaundice C1857143

Published: July 22, 2026Updated: August 20, 2026

A neurological condition affecting myelin development along with liver dysfunction causing jaundice. Typically presents in infancy. Requires supportive management addressing both neurological and liver concerns.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Neonatal jaundice

(neurologic)

Hypotonia

(neurologic)

Developmental delay

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Phototherapy for neonatal jaundice

Blue light therapy to convert bilirubin into water-soluble forms for excretion. Standard first-line treatment for hyperbilirubinemia in dysmyelination disorders.

procedure
3

Exchange transfusion

Blood exchange procedure to rapidly reduce bilirubin levels and remove circulating toxins. Reserved for severe cases or when phototherapy fails.

procedure

Additional treatment options

Specialized metabolic formula supplementation

Nutritional support with formulas designed for metabolic disorders, potentially including medium-chain triglycerides and reduced long-chain fats to support liver function.

dietary

Serial bilirubin and liver function monitoring

Regular laboratory assessment of bilirubin levels and hepatic function to guide treatment intensity and detect complications early.

monitoring

Ursodeoxycholic acid therapy

Bile acid supplementation to support liver function and improve bile flow. May help manage cholestasis component of the disorder.

medication

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dysmyelination With Jaundice C1857143?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dysmyelination With Jaundice C1857143. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy